President and Chief Executive Officer
Stanley C. Erck
Senior Vice President, Corporate Development
Senior Vice President, Research and Development
Gregory M. Glenn, M.D.
Senior Vice President, Global Manufacturing Operations
Timothy J. Hahn, Ph.D.
Senior Vice President, General Counsel & Corporate Secretary
John A. Herrmann III, J.D.
Senior Vice President, Process Development Operations
Cynthia N. Oliver, Ph.D.
Senior Vice President, Chief Financial Officer and Treasurer
Barclay A. "Buck" Phillips
Senior Vice President, Commercial Operations
John J. Trizzino
Senior Vice President, Business Development
Russell P. "Rip" Wilson
Vice President, Global Program Management
Denise Courbron, M.S., PMP
Vice President, Regulatory Affairs
Amy B. Fix
Vice President, Chief Medical Officer
Louis F. Fries III, M.D.
Vice President, Manufacturing
Mervyn L. Hamer
Vice President, Process Development
Erica Shane, Ph.D.
Vice President, Vaccine Development
Gale Smith, Ph.D.
Vice President, Clinical Operations
D. Nigel Thomas, Ph.D.
Mr.Erck was named President and Chief Executive Officer of Novavax in April 2011. He became a Novavax Director in June 2009 and beginning in February 2010, served as its Executive Chairman of the Board. From 2000 to 2008, Mr. Erck was President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and the MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Mr. Andréasson joined Novavax in June 2014 as Senior Vice President, Corporate Development. He will be responsible for identifying, prioritizing and evaluating new strategic opportunities that leverage the company's core strengths and growth initiatives. Mr. Andréasson brings to Novavax a long history of experience in biopharmaceutical operations, executive management and strategic development from his many years in the industry. From 2012 to 2013 he served as the Chief Executive Officer of Isconova AB in Uppsala, Sweden, a leading international vaccine adjuvant company acquired by Novavax in 2013, currently operating as Novavax AB. Prior to his role at Novavax AB, Mr. Andréasson served as the Chief Executive Officer of Beta-Cell NV in Brussels, Belgium from 2008 to 2012 and as Chief Executive Officer of Active Biotech AB in Lund, Sweden from 1999 to 2008. Mr. Andréasson spent a number of years in roles inside Pharmacia Corporation including: President of Pharmacia SA, France, President of KabiPharmacia International and President of Pharmacia Arzneimittel GmbH, Germany.Mr. Andréasson received his degree of Bachelour of Science in Business Administration and Economics from the Stockholm School of Economics, Sweden.
Dr. Glenn is a pioneer in vaccine delivery and adjuvants, and has brought several products from concept into clinical development, such as the travelers' diarrhea vaccine patch and an adjuvant patch for a pandemic influenza vaccine, developed under U.S. government contracts. He provided the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008. He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications, and holds multiple U.S., European and other international patents. In addition, he is an associate editor of the journals Expert Review of Vaccines, and Human Vaccine, and was a board-certified pediatrician. Dr. Glenn received his Bachelor of Arts degree in Biology and Chemistry from Whitman College and his Doctor of Medicine degree from Oral Roberts University School of Medicine. He also completed the Medical Research Fellowship at the Walter Reed Army Institute of Research.
Dr. Hahn is Senior Vice President of Global Manufacturing Operations with responsibility for manufacturing operations in the U.S. and Europe. He joined Novavax as Senior Vice President, Manufacturing and Process Development in June 2011. Dr. Hahn has more than 22 years of commercial vaccine and antibody manufacturing experience and a proven track record of successful performance in clinical and commercial production, facility start-up, process innovation, technology transfer, and regulatory inspections. Prior to joining Novavax, he was Vice President of Antibody Manufacturing and later Vice President of Vaccine Manufacturing at MedImmune, LLC, with responsibilities for sites in the U.S. and Europe. Prior to MedImmune, Dr. Hahn spent more than 15 years in vaccine manufacturing with Merck & Co. He received his Doctorate and Master of Science degrees in Chemical Engineering from Stanford University and his Bachelor of Science degree in Chemical Engineering from Lehigh University.
Mr. Herrmann joined Novavax in 2010 and is responsible for managing all of Novavax' legal affairs, including its patent portfolio, transactional and contractual matters, public securities filings, and attending to all the duties of Corporate Secretary. Mr. Herrmann also works with the senior management team at Novavax to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann was General Counsel at Ore Pharmaceuticals and Deputy General Counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann worked as Senior Counsel for Celera Genomics and before that was Senior Corporate Counsel at Baxter Healthcare in its Renal Division. Mr. Herrmann holds his Juris Doctorate from the University of Illinois and a Bachelor of Arts degree in Political Science and History from Brown University.
Dr. Oliver became Senior Vice President, Process Development Operations at Novavax in April 2014. Dr. Oliver has been a consultant of Novavax since 2011 where her significant expertise and experiences have helped the Company formulate and execute on critical process development strategies. Dr. Oliver is responsible for all of the Company's process development activities. From 1993 until 2010, Dr. Oliver held a variety of positions, including Vice President, Process Biochemistry and Formulation Sciences at Medimmune, Inc., with responsibilities that included vaccines, proteins, monoclonal antibodies and small molecules, including the commercial products Synagis® and FluMist®. Prior to MedImmune, she had similar responsibilities at Merck Research Laboratories, and spent a number of years working at the National Institutes of Health in the National Heart, Lung and Blood Institute. She earned her doctorate from Johns Hopkins, her masters from University of Massachusetts, and her bachelor's degree from Connecticut College.
Mr. Phillips joined Novavax in June 2013 as Senior Vice President and Chief Financial Officer, with responsibility for managing all of Novavax’ financial strategy, treasury and communications functions. He was most recently Senior Vice President and Chief Financial Officer of Micromet, Inc. which was acquired by Amgen in 2012. Previously, he was Managing Director of Vector Fund Management and a Biotechnology Analyst and Director of Venture Investments at Invesco Funds Group, Inc. Mr. Phillips received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.
↑ Back to Top
Senior Vice President, Commercial Operations
John J. Trizzino
Mr. Trizzino joined Novavax in March 2014 as the Senior Vice President, Commercial Operations with responsibility over the development and implementation of the commercialization strategy for the company's lead product candidates: RSV, seasonal influenza and pandemic influenza vaccines. Mr. Trizzino has extensive experience in the pediatric and adult vaccine market. He previously served as Novavax' Senior Vice President, International and Government Alliances beginning in 2009 and its Senior Vice President, Business Development from 2010 to 2011, during which he played a key role in negotiating the company's $179 million contract with HHS BARDA. Most recently, Mr. Trizzino was the CEO of Immunovaccine, a publically traded Canadian based biotech focused on the cancer immunotherapy market. While at MedImmune, Mr. Trizzino had responsibility for trade relations and corporate accounts for Synagis, a monoclonal antibody with $1 billion in annual revenue used for the prevention of RSV in premature babies. Mr. Trizzino also had the marketing and public health sales responsibility for MedImmune's highly differentiated nasally administered influenza vaccine FluMist. Mr. Trizzino was formerly the Senior Vice President, Business Development at ID Biomedical and Vice President, General Manager of the GIV division of Henry Schein, Inc. and then their Vice President, Business Development in the Medical Group. He received his BS from Long Island University, CW Post and his MBA from New York University, Stern School of Business.
Mr. Wilson joined Novavax in November 2011 as Senior Vice President, Business Development. He is responsible for developing business alliances, license arrangements, and partnering opportunities with pharmaceutical companies and government agencies. Mr. Wilson was most recently the Chief Financial Officer at Supernus Pharmaceuticals. He was previously Senior Vice President, Chief Financial Officer and General Counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG, during which time he successfully negotiated a $128 million government contract with the Office of Biomedical Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services. Mr. Wilson was also the Acting General Counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000. He is a graduate of Princeton University and received his Master's in Business Administration and Juris Doctorate degrees from the University of Virginia.
Denise Giangola Courbron, M.S., PMP, VP, Global Program Management, leads Novavax’ program management efforts covering all vaccine development programs. She joined Novavax in 2010 as Executive Director, Global Program Management, and was instrumental in Novavax being awarded its $179 million influenza development contract with HHS/BARDA in 2011. Prior to joining Novavax, Ms. Courbron directly supported licensure of multiple vaccines, and held positions of increasing responsibility in the biotechnology industry, including PharmAthene, Intercell USA, PPD, Iomai Corporation, Baxter BioScience, GloboMax (ICON) , and North American Vaccine. Prior to entering the vaccines industry, Ms. Courbron was with the U.S. Department of Defense, National Security Agency. Ms. Courbron received a B.A. in Political Science from Western Maryland College (McDaniel) and an M.S. in Biotechnology Management from the University of Maryland University College. She is a certified Project Management Professional.
Ms. Fix joined Novavax in April 2013 as Vice President, Regulatory Affairs with responsibility for regulatory strategy and our interactions with international regulatory agencies, including the U.S. Food and Drug Administration and the European Medicines Agency, which oversee the development and commercialization of our vaccine product candidates. She was most recently Senior Director of Regulatory Affairs at Emergent Biosolutions after serving in regulatory-affairs positions of increasing responsibility at a number of pharmaceutical companies, including Human Genome Sciences, Shire, MedImmune and Baxter. Ms. Fix received a Bachelor of Science degree in Biology from the University of Illinois, a Master of Science degree in Molecular Biology from the University of Virginia, and an M.B.A. from Johns Hopkins University.
Dr. Fries, who joined the Novavax team in 2011, has 22 years of experience in the clinical testing and development of human vaccines in academic, small biotech, and major biopharmaceutical environments. While a major career focus has been influenza, he has also had extensive involvement with bacterial and parasitic vaccines and therapeutic and prophylactic immunoglobulins. He has been an author of over 60 peer-reviewed publications. Most recently, following the acquisition of ID Biomedical by GSK Biologicals, Dr. Fries served as Director of Clinical Development from 2005 to 2011. He had previously served as Vice President of Clinical and Regulatory Affairs for Intellivax and ID Biomedical GSK Biologicals, which he had come to after 4 years as Director of Clinical Development for Univax and Nabi. Prior to joining the biotechnology industry, Dr. Fries served for 4 years as a faculty member in the Department of International Health, Johns Hopkins School of Hygiene and Public Health. Dr. Fries received his undergraduate training at the Johns Hopkins University and his Doctor of Medicine degree from Duke University. He trained in internal medicine at Johns Hopkins and infectious disease at the National Institutes of Allergy and Infectious Disease, where he was a member of the Laboratory of Clinical Investigation from 1979 to 1989.
Mr. Hamer joined Novavax in January 2012 as Vice President, Manufacturing, bringing with him more than 30 years of experience in the pharmaceuticals and biotechnology manufacturing industry. Prior to joining Novavax, he was Vice President of Supply Chain Management and Engineering at Intercell USA and Vice President of Operations at Iomai Corporation, its predecessor company. Before Iomai, Mr. Hamer had worked at both PATH and Alza Corporation, where he served as Technical Director and Director of Manufacturing, respectively. Mr. Hamer received his Bachelor of Science degree in Chemical Engineering from Worcester Polytechnic Institute.
Dr. Shane joined Novavax in November 2011 as Vice President, Process Development. She will have responsibility for all process development activities at Novavax. In addition she will provide oversight of process validation and technical support for manufacturing. Dr. Shane was most recently Senior Director of BioProcess Engineering at MedImmune. In this position, she was responsible for technology transfer to clinical and commercial sites as well as scale-up of cell culture and purification processes. Dr. Shane joined the purification department in 1994 and spent 12 years developing clinical and commercial purification processes. Her contributions were critical to the successful launch of Synagis®, a monoclonal antibody medication to help protect high-risk babies from severe RSV disease. In 2005, she assumed leadership of clinical manufacturing rising to the position of Senior Director in 2008. During the course of her tenure, Dr. Shane contributed to over 20 pipeline product programs. Prior to joining MedImmune, she held positions at DNX Corporation and American Cyanamid. Dr. Shane received her doctorate degree from Carnegie Mellon University, and her bachelor's degree from the Massachusetts Institute of Technology, both in chemical engineering.
Dr. Smith is a leader in vaccine technology and holds numerous patents for the baculovirus-insect cell expression system, influenza vaccines and adjuvants. At Novavax, Dr. Smith has developed the first known commercial, scalable process for the manufacture of virus-like particle vaccines for influenza. He also has collaborated with the U.S. Centers for Disease Control and Prevention in testing a virus-like particle vaccine to protect animals against the H9N2 influenza. Prior to joining Novavax, Dr. Smith led a team at Protein Sciences Corp. that developed the first experimental vaccine for HIV approved by the U.S. Food and Drug Administration for testing in the United States. Dr. Smith also collaborated with the National Institute of Allergy and Infectious Diseases and the National Institute of Health to produce the first experimental vaccine tested in man against the H5N1 avian influenza. Dr. Smith did graduate work at the Baylor College of Medicine and has a Ph.D. in Microbiology from Texas A&M University.
Dr. Thomas joined Novavax in April 2011 as Executive Director, Clinical Operations, with responsibility for clinical trial execution of all clinical-stage programs both in the U.S. and worldwide. He was most recently the Clinical Operations Director at Iomai beginning in 2006 and through acquisition by Intercell. He has previously held a variety of clinical operation positions in the Biotechnology and CRO industry and was a MacArthur Foundation Postdoctoral Fellow at the National Institute of Mental Health. He has overseen numerous vaccine, drug and medical device clinical trials including global Phase 2 and Phase 3 clinical trials for vaccines. Dr. Thomas received a Bachelor of Science degree in Pathobiology with a minor in Chemistry, and a Ph.D. in Biochemistry and Physiology from the University of Reading, United Kingdom.